HIPEC after Interval Debulking Surgery as Best Clinical Practice in Ovarian Cancer Patients: Case Series and Literature Review

Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with interval debulking surgery (IDS) constitutes an adjunctive treatment strategy in advanced ovarian cancer (AOC). This approach is based on the concept of perfusing chemotherapy targeting directly the site of residual tumor af...

Full description

Saved in:
Bibliographic Details
Main Authors: Stefano Restaino (Author), Jessica Mauro (Author), Stefano Cianci (Author), Alessandro Buda (Author), Claudia Andreetta (Author), Elena Poletto (Author), Enrico Maria Pasqual (Author), Alice Poli (Author), Cosimo Vittorio Agrimi (Author), Doriana Armenise (Author), Alice Buzzelli (Author), Domenico Caccamo (Author), Lorenza Driul (Author), Giuseppe Vizzielli (Author)
Format: Book
Published: IMR Press, 2022-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_efa8d3eb2e3a472aabcd2a3b43b9cd5c
042 |a dc 
100 1 0 |a Stefano Restaino  |e author 
700 1 0 |a Jessica Mauro  |e author 
700 1 0 |a Stefano Cianci  |e author 
700 1 0 |a Alessandro Buda  |e author 
700 1 0 |a Claudia Andreetta  |e author 
700 1 0 |a Elena Poletto  |e author 
700 1 0 |a Enrico Maria Pasqual  |e author 
700 1 0 |a Alice Poli  |e author 
700 1 0 |a Cosimo Vittorio Agrimi  |e author 
700 1 0 |a Doriana Armenise  |e author 
700 1 0 |a Alice Buzzelli  |e author 
700 1 0 |a Domenico Caccamo  |e author 
700 1 0 |a Lorenza Driul  |e author 
700 1 0 |a Giuseppe Vizzielli  |e author 
245 0 0 |a HIPEC after Interval Debulking Surgery as Best Clinical Practice in Ovarian Cancer Patients: Case Series and Literature Review 
260 |b IMR Press,   |c 2022-06-01T00:00:00Z. 
500 |a 0390-6663 
500 |a 10.31083/j.ceog4906143 
520 |a Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with interval debulking surgery (IDS) constitutes an adjunctive treatment strategy in advanced ovarian cancer (AOC). This approach is based on the concept of perfusing chemotherapy targeting directly the site of residual tumor after optimal surgical debulking. It improves patients' outcome in terms of overall survival (OS) and disease free survival (DFS). The correct selection of patients eligible for IDS + HIPEC is crucial: in particular, they must have shown a good response to neoadjuvant chemotherapy (NACT) and have a good performance status (PS). The application of HIPEC at the end of debulking does not seem to increase neither the rate of intra/postoperative complications nor the time of hospitalization. Clinical Cases: After approving an internal protocol for the application of HIPEC in our hospital, we have submitted four patients to IDS + HIPEC in the past 12 months. One of these patients underwent a minimally invasive procedure. No intra- or postoperative complications were observed. Results: All patients underwent IDS + HIPEC after being assessed as eligible and after showing a good response to NACT. In the course of IDS in all cases complete debulking was achieved. No patient developed intra- or postoperative complications. Conclusions: The addition of HIPEC to interval debulking surgery should be offered to all eligible patients, considering that the association of HIPEC to IDS seems to improve patients' outcomes in terms of OS and DFS, without increasing post-operative morbidity . 
546 |a EN 
690 |a advanced ovarian cancer 
690 |a hipec 
690 |a interval debulking surgery 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
655 7 |a article  |2 local 
786 0 |n Clinical and Experimental Obstetrics & Gynecology, Vol 49, Iss 6, p 143 (2022) 
787 0 |n https://www.imrpress.com/journal/CEOG/49/6/10.31083/j.ceog4906143 
787 0 |n https://doaj.org/toc/0390-6663 
856 4 1 |u https://doaj.org/article/efa8d3eb2e3a472aabcd2a3b43b9cd5c  |z Connect to this object online.